New hope for tough lymphoma: drug combo shows promise in early trial
NCT ID NCT01959698
First seen Jan 30, 2026 · Last updated Apr 30, 2026 · Updated 10 times
Summary
This early-phase study tested a new combination of drugs (carfilzomib plus standard chemotherapy) in 29 adults with diffuse large B-cell lymphoma that had come back or not responded to prior treatment. The main goals were to find the safest dose of carfilzomib and see how well the combo works at shrinking tumors. While the approach aims to control the disease, it is not a cure, and ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.